Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Authors
Publication date
1 November 2011
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    University of Queensland eSpace

    redirect
    oaioai:espace.library.uq.edu.au:U...
    Last time updated on 30/08/2013